

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 1 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

**University Hospitals
of Leicester**
NHS Trust

Caring at its best

Cytogenetics User Handbook

A user guide for UHL Cytogenetic Laboratory Pathology services

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 2 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

Contents

Cytogenetics	1
User Handbook	1
1.0 Introduction	4
2.0 Scope of the service	4
3.0 General Information	5
3.1 Location of services	5
3.2 Opening hours	5
3.3 Contact information	5
3.4 Why is genetic testing undertaken in the laboratory?	6
3.5 Protection of personal data	6
3.6 User feedback	6
3.7 Complaints and concerns	7
4.0 Requesting procedures	7
4.1 Sample collection and specimen types	7
4.2 Specimen Labelling	8
4.3 Completion of request forms	8
4.4 Consent for testing	9
4.5 Additional testing on a sample	9
4.6 Verbal requests	9
4.7 Fibroblast cultures for onward referral	10
5.0 Transport of specimens to the laboratory	10
5.1 Transport of samples within UHL	10
5.2 Samples from external hospitals	10
5.3 Sending samples to the Genomic Laboratory Hub (GLH)	11
5.4 High risk specimens	11
6.0 Constitutional investigations	11
6.1 Postnatal microarray	12
6.2 Postnatal karyotyping	13
6.3 Rapid aneuploidy testing	13
6.3.1 Rapid aneuploidy testing for the Fetal Anomaly Screening Programme (FASP)	13
6.4 Prenatal microarray	14

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 3 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

6.5 Prenatal karyotyping	14
6.6 Pregnancy loss investigation	15
7.0 Fluorescent in situ hybridisation (FISH).....	15
8.0 Acquired haemato-oncology investigation	16
9.0 Molecular pathology investigation	17
9.1 PCR testing.....	18
9.2 NGS testing	18
10.0 Molecular genetic and genomic testing	18
11.0 Availability of results.....	19
12.0 Turnaround times	20

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 4 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

1.0 Introduction

The information contained in this user handbook is designed to meet the needs and requirements of our service users. This handbook includes detailed information on the service available within the Cytogenetics Laboratory service at University Hospitals of Leicester (UHL).

If you require any further information on any aspect of the service or have a comment or suggestions on how we can improve please contact us via email at cytogenetics@uhl-tr.nhs.uk or telephone 0116 258 5637.

If you require clinical advice, please contact the laboratory and ask to speak with the Head of Service or one of the senior clinical scientist team.

2.0 Scope of the service

The cytogenetics laboratory is a Consultant Clinical Scientist led team that includes HCPC registered Clinical Scientists, Genetics Technologists and Biomedical Assistants

We offer an analysis and clinical interpretation service on a range of prenatal, postnatal, haematological and cancer samples using traditional karyotyping, FISH, microarray (CGH & SNP), single gene variant analysis and next generation sequencing (NGS).

The Laboratory is externally accredited by UKAS (ref 8069) to the ISO15189 (2022) Medical Laboratory standard and participates in the relevant Genetics External Quality Assessment Schemes (GenQA) and UK NEQAS Leucocyte Immunophenotyping Scheme to cover the full repertoire of our services and ensure the highest standards.

The laboratory is co-located and works in conjunction with the [Clinical Genetics Service](#).

The Cytogenetic Laboratory Service is a subcontracted Local Genomic Laboratory (LGL) of the [East Genomic Laboratory Hub \(GLH\)](#) led by Cambridge University Hospital Foundation Trust. Nottingham University Hospitals NHS Trust are also an LGL for the East GLH.

The GLH provides testing in line with the [NHS England genomic test directories](#) for rare disease and cancer and associated eligibility criteria. Cytogenetic investigations, and some single gene and NGS cancer testing are undertaken within the UHL laboratory on behalf of the GLH.

There is no Molecular Genetics service within UHL for rare disease. Samples are sent to the required laboratory within the East GLH network for testing based on the referral reason in line with the GLH contract. Advice on sample requirements and the testing laboratory to be

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 5 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

used can be obtained from the [cytogenetics laboratory](#) or by contacting the [GLH duty scientist](#) by email.

Please note that we do not accept self-referrals from patients and that all results are strictly confidential.

3.0 General Information

3.1 Location of services

The Laboratory is located in the Genetics centre on the Leicester Royal Infirmary (LRI) site of UHL. Molecular pathology testing is carried out in a laboratory within the Robert Kilpatrick Clinical Sciences building (RKCSB) also on the LRI site.

3.2 Opening hours

The laboratory is open 9.00-17.30 Monday to Friday. There is no out of hours service

3.3 Contact information

Contact the laboratory if you require clinical advice or have any questions regarding the available service, results or sample requirements.

Enquiry line 0116 258 5637

Key staff contacts:

Head of service: [Lara Cresswell](#) FRCPATH
Trainee Consultant Clinical Scientist, Deputy head of service
[Paul Warman](#)

Principal Clinical Scientists & Section Heads:
[Karen Healey](#) – Constitutional Section
[Karen Marshall](#) – Haematology and FISH
[Claire Slater](#) – Molecular pathology

Operational Manager: [Rajesh Thakrar](#)
Laboratory Co-ordinator: [Anne-Marie Rocks](#)
[General enquiries](#) mailbox – cytogenetics@uhl-tr.nhs.uk
[East GLH duty scientist](#) - cuh.geneticlaboratories@nhs.net

Please note that UHL email addresses conform to DCB 1596 accreditation. University Hospitals of Leicester is a NHS Secure Email Accredited Organisation, accreditation can be assured via the NHS link - <https://digital.nhs.uk/services/nhsmail/the-secure-email-standard#list-of-accredited-organisations>

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 6 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

3.4 Why is genetic testing undertaken in the laboratory?

Chromosome abnormalities usually involve large amounts of DNA that can be rearranged, deleted or duplicated. Chromosome analysis may be carried out to investigate fertility issues, confirm some common chromosomal syndromes such as Down syndrome and to look for acquired chromosome changes associated with leukaemia.

Microarray investigation allows the identification of very small losses and gains of genetic material that are too small to be seen on chromosome analysis. Using a patient's DNA rather than their chromosomes very small loss and gain can be identified. In addition, where a particular type of microarray is used (a SNP array) uniparental disomy and absence of heterozygosity (AOH) may be identified. Microarray investigation is used in prenatal diagnosis and in the investigation of dysmorphism, congenital malformations and intellectual disability.

Molecular pathology testing is an important part of the diagnosis of cancer as acquired genetic changes can be of diagnostic, prognostic and therapeutic significance.

3.5 Protection of personal data

All laboratory staff undertake mandatory Information Governance training ensuring that patient information is handled legally, securely and confidentially.

UHL's privacy notice can be found on the main website at <https://www.leicestershospitals.nhs.uk/aboutus/education-and-research/research-innovation/about-us/privacy-notice/>

This Notice explains:

- Who we are, how we use your information and who our Data Protection Officer (DPO) is
- What kinds of personal information about you we process
- What the legal grounds for our processing of your personal information are (including when we share it with others)
- What you should do if your personal information changes
- How long do we retain your personal information?
- What your rights under data protection law are
- The Trust's public membership policy

3.6 User feedback

The laboratory welcomes and encourages feedback and comments from our users regarding any aspect of our service. All sections within the laboratory can be contacted on 0116 258 5637 or extension 15637 or email; cytogenetics@uhl-tr.nhs.uk

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 7 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

3.7 Complaints and concerns

We aim to provide an excellent service however any complaints or concerns about our service, from patients or referring clinicians, will be dealt with according to the UHL Management of complaints policy. Complaints may be directed to the Head of Service in the first instance or direct to the Patient Information Liaison Service (PILS).

4.0 Requesting procedures

The laboratory provides specific cytogenetic referral forms for different test types, sample bags can be attached, and some patient information leaflets. Please contact the laboratory to obtain a relevant supply. The forms give information on the sample types and volumes required. Cytogenetic tests cannot be requested electronically with the exception of JAK2.

Referrals for molecular testing to be undertaken at the GLH are sent to the cytogenetics laboratory at UHL where they are collated and sent to the relevant GLH lab via the daily courier service. The cytogenetics laboratory holds a record of the sample received and where they are sent but does not have access to the results for these investigations.

Please note that we do not accept self-referrals from patients and that all results are strictly confidential.

4.1 Sample collection and specimen types

All samples should be sent to the laboratory as soon as possible. Where samples are taken out of hours samples should be stored in a fridge and sent on the next working day.

Blood samples – please ensure samples are well mixed to prevent clotting
 for karyotyping and/or FISH: lithium heparin tube; minimum 1ml
 for microarray: EDTA tube
 for JAK2 PCR : EDTA tube

Amniotic fluid samples – all investigations: minimum 15mls taken into a sterile universal container

Chorionic villus - all investigations: minimum 10mg villus sent in transport media (available from the laboratory)

Bone marrow - all investigations: minimum 1ml of marrow sent in transport media (available from the laboratory)

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 8 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

Skin biopsies: full dermal thickness sent in sterile physiological saline or transport media (available from the laboratory)

Solid tissue samples: sent in sterile physiological saline or transport media (available from the laboratory)

Products of conception (POC): POC samples must contain chorionic villus material or fetal parts. DO NOT send the entire evacuation products. Samples from UHL must be sent according to the UHL policy for sensitive disposal of fetal remains up to 16 weeks. Samples from other hospital trusts must comply with their own policy and provide evidence of disposal wishes with the sample.

Placental samples (from pregnancy losses): Placental samples will only be accepted if taken from the fetal side of the placenta. Cord samples should be taken from near the cord insertion site.

Formalin fixed paraffin embedded tissue (FFPE):

For FISH – 2µm sections on sticky slides sent de-waxed

For NGS - <30% tumour cellularity 5x4µm slides with marked H&E from either end

->30% tumour cellularity 2x10µm curls in an eppendorf an marked H&E from either end

Where a suboptimal sample is received this may lead to a longer reporting time.

4.2 Specimen Labelling

To avoid errors in identification, samples must be clearly marked with the patient's full name and date of birth. This information should correspond exactly with the information on the request form.

If there is any discrepancy the processing of the sample may be delayed until the information is checked. Ultimately the sample may be discarded if the patient cannot be positively identified. Unlabelled samples that cannot be reliably identified to a patient cannot be accepted for analysis.

4.3 Completion of request forms

Cytogenetic request forms should be used and be fully completed and signed by the requesting clinician. If available, addressograph labels should be used on request forms.

All forms must show patient details (at least first name and family name and date of birth), referring consultant, referring hospital, date of sample, full clinical details and where possible

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 9 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

the appropriate [test directory test code](#). Wherever possible the NHS number should be included on the form.

There are different coloured referral forms available from the laboratory however please contact our [mailbox](#) if you require a form urgently and we can email one to you.

The [Genomic Laboratory Hub referral forms](#) can also be used and are available from the East GLH website. The forms give details of the sample types and volumes required.

UHL referral forms – contact the laboratory for a supply:

White cytogenetics referral form should be used to request karyotyping.

Green, postnatal microarray referral form should be used to request postnatal microarray investigation.

Lilac, prenatal microarray referral form should be used to request prenatal microarray investigation.

Pale blue JAK2 referral form should be used to request JAK2 V617F testing.

Orange molecular pathology referral form should be used to request NGS testing for solid cancer.

The UHL pregnancy loss form should be used to request microarray investigation following pregnancy loss.

4.4 Consent for testing

All genetic testing requires consent. The responsibility for obtaining informed consent for genetic testing lies with the referring clinician. The laboratory assumes that by provision of a sample and completed referral form that consent has been obtained by the referring clinician. Documentation relating to this consent should be retained in the patient's clinical notes.

A [record of discussion form](#) is available on the East GLH website that can be helpful in recording consent.

4.5 Additional testing on a sample

There are some limited circumstances where additional tests may be undertaken on the original sample. Please contact the laboratory for advice before taking a further sample.

4.6 Verbal requests

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 10 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

Where a verbal request is made for testing the referring clinician must provide written confirmation of the verbal request. Laboratory staff will inform service users of this procedure if the verbal request is accepted.

4.7 Fibroblast cultures for onward referral

The laboratory will only grow fibroblasts cultures for onward referral by prior agreement, and an onward referral letter will be required upon receipt of the sample. The referring clinician will be responsible for selecting the testing laboratory.

5.0 Transport of specimens to the laboratory

Samples (especially bone marrow and prenatal samples) should be received in the laboratory as quickly as possible.

Samples must not be centrifuged or frozen or have been processed by another laboratory.

Out-of-hours samples should be stored in a refrigerator and sent the next working day. Significant delay in sending samples may result in the sample being unsuitable for processing.

Specimens must be placed in a sealed sample bag. In order to avoid accidental contamination, please do not place request forms in the same bag as the specimen pots.

5.1 Transport of samples within UHL

Samples can be sent to Pathology Specimen Reception (Sandringham level 2, LRI) using the regular LRI clinical distributor service for delivery to Cytogenetics or bought direct to the laboratory by portering services.

Samples from LGH or GH can be sent via the regular inter-hospital van transport and delivered to Pathology specimen reception for onward delivery by the clinical distributors.

5.2 Samples from external hospitals

Where samples are sent by post they must comply with [current regulations](#) (P650) on the transport and postage of biological materials and display the UN3373 symbol.

Samples should be placed in sealed specimen bags with the form attached to the outside and then placed in rigid outer packaging. It is recommended that samples are sent via Royal Mail special/tracked delivery or courier to ensure sample receipt can be confirmed.

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 11 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

5.3 Sending samples to the Genomic Laboratory Hub (GLH)

Samples from UHL and some other external hospitals or GPs that require molecular genetic/genomic testing are received by the cytogenetics laboratory and sent on to either the Nottingham Molecular Genetics laboratory or the GLH lab at Cambridge depending on the test directory code that is required. Transport is via a dedicated courier service provided by the GLH and staff in the cytogenetics laboratory will ensure samples are appropriately packaged for transport with the courier.

Samples will be logged for transit audit purposes, reports are not received back in the cytogenetics laboratory but sent direct to the referring clinician.

5.4 High risk specimens

The cytogenetic laboratory does NOT have a category 3 containment facility. This means any sample suspected of having or having a pathogen that requires containment level 3 (e.g. TB) cannot be accepted by the department for culturing.

It is the responsibility of the requesting clinician to ensure that all high risk or potentially high risk specimens are handled correctly and dealt with in the following manner:

Acceptable samples suspected or known to contain hazardous pathogens are restricted to hepatitis B, hepatitis C, and HIV. Samples must be labelled with 'Danger of Infection' stickers. A sticker must also be attached to the request form, and both form and sample placed in a 'bio-hazard' bag.

The sample container must be appropriate for the purpose, must be properly closed and not externally contaminated by the contents.

The form must be placed in the separate pocket of the bag, NOT inside with the sample. Where bags are attached to the form the bag should be sealed shut after placing the sample inside.

The referral form must be fully completed including contact details of the clinician taking the sample. To avoid a delay in processing a high risk sample the laboratory must be able to contact the referring clinician.

Please inform the laboratory if the patient is subsequently shown not to carry the pathogen.

6.0 Constitutional investigations

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 12 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

The laboratory can undertake investigation of constitutional genetic conditions using karyotyping, microarray or fluorescent in situ hybridisation (FISH). The most appropriate method will be selected by the clinical scientists based on the clinical details provided and the relevant test directory code.

The constitutional section head is [Karen Healey](#). If you have any questions regarding sample requirements or results please contact the laboratory on ext. 15637 or [email](#).

6.1 Postnatal microarray

Microarray comparative genomic hybridisation (CGH) allows a genome wide screen at a high resolution for the detection of previously cryptic copy number imbalance (deletions and duplications).

The service uses Agilent ISCA 8x60k oligonucleotide arrays that give a functional resolution across the genome of 180kb.

Microarray investigation using the Illumina Infinium GSA SNP array is also offered to certain pre-agreed users. This has a functional resolution across the genome of 180kb but in addition is able to identify uniparental disomy and absence of heterozygosity (AOH). For the GSA array the processing is undertaken by the GLH main lab at CUH with analysis undertaken by the team in cytogenetics. Whilst the GSA array has been fully validated this testing is not yet on the laboratory's ISO 15189 schedule of accreditation. An extension to scope will be submitted soon.

A green specific microarray referral form or GLH rare disease referral form should be fully completed; this lists the sample types and volumes required.

Microarray analysis is undertaken using a patient's DNA. Therefore an EDTA blood sample is required. DNA is extracted in the cytogenetics laboratory for the Agilent array or at the CUH laboratory for the GSA array.

A patient information leaflet is available from the referral areas and the laboratory.

For neonatal microarray referrals a lithium heparin sample is also required if rapidFISH for a common aneuploidy is required e.g. Down syndrome is suspected; this will be undertaken prior to the array. Where a rapidFISH investigation is shown to be abnormal microarray investigation will not be undertaken, the FISH result will be confirmed by a targeted chromosome analysis.

Referrals for Turner syndrome will have an initial rapidFISH investigation to decide if a microarray or karyotype investigation is required. Both lithium heparin and EDTA samples are required for this referral type.

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 13 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

6.2 Postnatal karyotyping

Microarray investigation is the first line test for the majority of postnatal blood referrals. Please see section 6.1.

Karyotyping is used for specific referrals reasons such as mosaicism screening and looking for balanced structural chromosome rearrangements. Please contact the laboratory for advice on the appropriate test and which referral form to use.

6.3 Rapid aneuploidy testing

Rapid screening for common aneuploidies is undertaken by FISH for relevant urgent neonatal referrals and for some prenatal samples. See section 7 for further information on FISH testing.

The common aneuploidies that can be investigated are trisomies 13, 18 and 21 and sex chromosome aneuploidy.

Amniotic fluid samples which are heavily bloodstained may not be suitable for rapid aneuploidy testing. Microarray investigation may also be delayed as a direct extraction of DNA may not be suitable.

6.3.1 Rapid aneuploidy testing for the Fetal Anomaly Screening Programme (FASP)

Rapid aneuploidy testing for the FASP is undertaken by the QF-PCR method at the GLH main laboratory at CUH. The fetal medicine units at UHL send samples to the cytogenetics laboratory where DNA will be extracted and sent to CUH for QF-PCR. Samples are cultured at UHL and any follow on microarray testing or chromosome analysis undertaken in the cytogenetics laboratory.

Samples requiring rapid aneuploidy testing must reach the laboratory before 3.30pm to allow DNA to be sent to CUH for QF-PCR the next working day. QF-PCR results are usually available within 24-48 hours of receipt in the CUH laboratory however the turnaround time is 3 calendar days from receipt of the DNA.

Please note any samples outside of the FASP e.g. invasive samples for prenatal single gene disorder familial testing will continue to have rapid aneuploidy testing by FISH.

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 14 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

6.4 Prenatal microarray

The Cytogenetics service offers a prenatal microarray investigation for samples referred due to an increased nuchal translucency and/or abnormalities seen on an ultrasound scan. All prenatal samples are received from the Fetal Medicine service.

The sample requirements for prenatal microarray are the same as for prenatal cytogenetics.

Microarray comparative genomic hybridization (CGH) allows a genome wide screen at a high resolution for the detection of previously cryptic copy number imbalance (loss or gain).

The service uses Agilent ISCA 8x60k oligonucleotide arrays that gives a functional resolution across the genome of 180kb.

A specific lilac referral form should be used for all prenatal microarray referrals. A specific patient information leaflet is available. These are in the referral areas and can be obtained from the laboratory.

Microarray analysis is undertaken on DNA extracted from the baby from the amniotic fluid or chorionic villus. DNA from an EDTA blood sample is also required from the mother and father (where possible). As a minimum an EDTA sample must be sent from the mother.

All samples will have a rapid aneuploidy test before microarray by QF-PCR. Where the QF-PCR result is abnormal it will be confirmed by a targeted chromosome analysis. Where the QF-PCR test is normal a microarray test will be undertaken. The QF-PCR test is able to indicate if there is any maternal cell contamination in the sample.

Long term storage of fetal DNA will be undertaken at the CUH laboratory where the QF-PCR investigation is carried out, appropriate consent must be obtained.

Where a suboptimal sample is received, or samples are taken late in the 3rd trimester, this may lead to a longer reporting time.

6.5 Prenatal karyotyping

Routine karyotyping is no longer carried out on samples received for a raised nuchal translucency or abnormalities found on ultrasound scan. Prenatal microarray investigation is the commissioned test.

Samples received due to a high risk Down Serum Screening Programme result will only have a rapid aneuploidy QF-PCR result which will be undertaken at the GLH main lab at CUH. Full karyotyping or microarray will not be undertaken however where the QF-PCR result is abnormal this will be confirmed by a targeted chromosome investigation.

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 15 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

Where a suboptimal sample is received, or samples are taken late in the 3rd trimester, this may lead to a longer reporting time.

6.6 Pregnancy loss investigation

Genetic investigation of pregnancy losses is undertaken using microarray. Referral reasons include recurrent miscarriage (3 or more), intrauterine death, still birth or a termination of pregnancy for abnormalities found on ultrasound scan. Referrals are accepted according to the referral criteria in the NHSE [rare disease test directory](#). The relevant test directory codes are R22.2 and R318.2. Please note that samples are not accepted from isolated pregnancy losses in the second trimester where there are no anomalies on the ultrasound scan.

There is a specific UHL pregnancy loss referral form which is an A4 form modified from the East GLH rare disease referral form. Word and pdf versions of the form can be obtained from the laboratory by [email](#)

Pregnancy loss samples can be amniotic fluid, chorionic villus, products of conception (POC), cord or skin.

POC samples must contain chorionic villus material or fetal parts. Please do not send the entire evacuation products. Consent for disposal must be sent with the sample.

Amniotic fluid samples and chorionic villus samples are generally taken by fetal medicine consultants as for prenatal cytogenetic investigations.

Samples cannot be processed if they have been exposed to formalin.

7.0 Fluorescent in situ hybridisation (FISH)

The Cytogenetic Laboratory has a range of probes available for fluorescent in situ hybridisation (FISH) testing. These include probes for both constitutional and acquired abnormalities.

The head of the FISH section is [Karen Marshall](#). If you have any questions regarding FISH testing please contact the laboratory on ext 15637 or [email](#).

FISH testing is a useful tool for identifying rearrangements which may be missed by traditional karyotyping and is particularly useful in haematological malignancy investigation. It can also be used to confirm some microarray findings. FISH analysis can be undertaken on chromosomes or interphase nuclei and from paraffin embedded tissue samples.

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 16 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

As microarray investigation will assess all constitutional microdeletion and microduplication syndromes this is the best method of analysis for such [postnatal](#) and [prenatal](#) referrals. If you require FISH testing for a specific syndrome please contact the laboratory to discuss the best method of investigation.

Rapid FISH screening is available for the common aneuploidies for all prenatal samples not part of the FASP and clinically relevant urgent neonatal referrals by prior agreement with the laboratory. The turnaround time for this test is within 3 calendar days.

Urgent FISH testing is a requirement for certain types of leukaemia and a preliminary FISH result should be available within 3 calendar days. These results are also available in the HMDL laboratory.

Where a routine FISH test is undertaken this is reported with the final report. **The turnaround time is based on the sample type received.**

Molecular genetic testing is the first line test for the specific investigation of Prader-Willi and Angelman syndrome. Microarray analysis is able to identify the common causes of these syndromes. Both tests require an EDTA blood sample. Please contact the laboratory for advice on the most appropriate test.

Some FISH probes may be used after the manufacturer's expiry date. These are not covered by our UKAS accreditation but have all been rigorously tested prior to reporting. A comment will be added to any reports where this has happened. Please contact the laboratory for any further information.

8.0 Acquired haemato-oncology investigation

The Haematology section performs chromosome analysis on haematological samples using traditional karyotyping and FISH analysis.

The Head of section is [Karen Marshall](#). If you have any questions regarding sample requirements or results please contact the laboratory on ext 15637 or [email](#).

Samples requiring cytogenetic testing should come to the laboratory via the HMDL laboratory (ext. 16518). The laboratory has specific criteria for its urgent classification.

Samples must be received as soon as possible after they have been taken. Old or clotted samples may not be successfully cultured.

Lithium heparin blood samples will generally only be accepted from CLL patients.

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 17 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

FISH studies will be undertaken as agreed with the HMDL Laboratory.

FISH studies on lymphoma referrals are undertaken for certain referrals as agreed with the HMDL laboratory. These studies are carried out using paraffin embedded tissue sections (PETS) and are referred by histopathologists. FFPE slides are prepared by the cellular pathology lab for these tests. Turnaround times for these requests are agreed on a case by case basis.

Bone marrow samples from patient's known or suspected of having Myeloma should only be referred if the plasma cell count is >10%. Samples should be transported to the laboratory as quickly as possible and **should not be taken on Friday** where possible as these may not be able to be processed on receipt. Cytogenetic investigation for Myeloma is carried out on purified plasma cells. Delays in sample transport or processing can reduce the number of plasma cells available for purification and subsequent analysis.

9.0 Molecular pathology investigation

Molecular testing is an important part of the diagnosis of patients with cancer as acquired genetic changes can be of diagnostic, prognostic and therapeutic significance.

The head of section is [Claire Slater](#). If you have any questions regarding sample requirements or results, please contact the laboratory on ext 15637 or [email](#).

Molecular profiling of tumours can help provide information on the most effective therapy for a certain type of solid or haematological tumour.

Specific DNA variants (mutations) can be associated with sensitivity to certain therapeutic drugs; they can also indicate when a patient is becoming resistant to treatment allowing a change to an alternative therapy.

The service undertakes testing for certain gene variants associated with some cancers including myeloproliferative neoplasms (MPNs), lung cancer, colorectal cancer, melanoma, breast cancer, GIST and cholangiocarcinoma. Other tumour sites may be accepted if the genes of interest are included on the ThermoFisher OncoPrint precision Assay (OPA) gene panel. Please contact the laboratory to discuss.

DPYD testing:

Targeted variant testing of the DPYD gene for 5-fluorouracil toxicity is undertaken by the East GLH at Cambridge.

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 18 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

9.1 PCR testing

PCR testing is routinely undertaken for the JAK2 V617F variant associated with myeloproliferative neoplasm. A commercial quantitative PCR kit is used and a variant allele frequency >1% is reported. Monitoring requests will only be undertaken on an annual basis, any samples received out with of this time scale will be rejected.

Targeted PCR testing for KRAS, EGFR & BRAF is currently on the laboratory's schedule of accreditation and can be used where an urgent result is required and the NGS panel is not possible within the required timescale.

9.2 NGS testing

Molecular testing for lung cancer, colorectal cancer, melanoma, breast cancer, GIST and cholangiocarcinoma referrals is undertaken using the Thermofisher Oncomine precision Assay (OPA) gene panel on the Genexus NGS platform. Whilst the OPA panel covers single nucleotide variants, copy number variants and fusions across 50 key genes each cancer type will be analysed for the defined set of genes, covered by the OPA, in line with the multitarget NGS panel test described in the [NHSE cancer test directory](#). In general, only actionable or driver variants are reported.

DNA and RNA extraction will be undertaken for all referred cases where possible to facilitate any downstream testing. This will be stored in the genetic laboratory.

Whilst the OPA assay has been fully validated this testing is not yet on the laboratory's ISO 15189 schedule of accreditation. An extension to scope will be submitted soon.

The technical details for all molecular cancer tests are included in the report produced by the cytogenetics laboratory. Where this information is not visible on results transcribed into different systems e.g. iLab then this information is available from the laboratory.

10.0 Molecular genetic and genomic testing

There is no molecular genetics service within UHL. Testing is undertaken at the relevant testing laboratory within the GLH network. Samples will be sent initially to either the GLH laboratory at Cambridge or the Nottingham Regional Molecular Genetics Service based at the Nottingham City Hospital.

The [East Genomic Laboratory Hub](#) (GLH) is based at Cambridge University Hospital Foundation Trust. The [laboratory](#) is accredited by UKAS to the ISO:15189 Medical Laboratories standard (ref 8840). The laboratory manager is [Mark Dance](#).

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 19 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

The service manager for the Nottingham Regional Molecular Genetics Service is [Amanda Corkill](#). The laboratory is accredited by UKAS to the ISO:15189 Medical Laboratories standard (ref 8044).

To find out which tests are undertaken at the Nottingham laboratory please see their [website](#), all other tests will be arranged via the Cambridge laboratory.

For clinical advice, results or sample requirements please contact the GLH duty scientist on [email](#) or the Nottingham laboratory on 0115 9691169 ext 55207 or by [email](#)

Referral forms for the GLH laboratory can be found [here](#) which are accepted at both CUH and NUH.

Please note that results from molecular genetic investigations are not available in the cytogenetics laboratory. Results are emailed to the referring clinician by the testing laboratory.

If you require molecular genetic/genomic testing, samples should be sent to the Leicester cytogenetic laboratory for onward referral to either Cambridge or Nottingham. Samples are transported via the GLH courier each morning Monday to Friday.

11.0 Availability of results

Results will only be given to authorised clinical staff and we may refuse to disclose results if you are not from the referring clinician's team.

All authorised reports are emailed as pdfs direct to the referring clinician or their nominated mailbox. Valid reports will have an authorising signature.

Cytogenetic reports for prenatal and postnatal samples are not available on iLab.

Verbal requests for results can be made providing the clinician is involved in the care of the patient. Callers must be able to reliably identify themselves. Results are not given directly to patients.

Cytogenetic reports for haematology and solid cancer referrals including JAK2 are also available in iLab.

Uncertainty of Measurement

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 20 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

The laboratory considers the uncertainty of measurement for all its procedures. Please contact the laboratory if further details on our approach to uncertainty are required.

Molecular Genetic/Genomic test results

The cytogenetic laboratory does not have access to molecular genetic/genomic results. These results are only available from the molecular genetics laboratory who performed or organised the testing and will be routinely emailed to the referring clinician.

For referrals prior to December 2020 please contact the Nottingham Molecular Genetics Laboratory on 0115 969 1169 ext 55207 or secure [email](#). Referrals received after this date may be available from Nottingham or the GLH laboratory who can be contacted by [email](#) in the first instance or on 01223 348866.

12.0 Turnaround times

The laboratory aims to meet the [NHSE required turnaround time](#) for all of our tests.

Turnaround times are monitored on a monthly basis and form part of our monthly assurance report.

Turnaround times are all in calendar days with the day of receipt being day 0.

Testing	subcategories	Turnaround time Calendar days	Examples
Postnatal microarray & chromosome analysis	Newborn <1 month Family testing where mother is pregnant	14 days	
	Routine	42 days	Intellectual disability Pregnancy loss
Rapid aneuploidy* FISH testing	Prenatal requests and newborn babies	3 days	
Prenatal microarray & chromosome analysis		14 days	
Haemato-oncology karyotyping	New AML/ALL/CML & relapse samples	14 days	
	Non-acute requests	21 days	MDS/MPN

Title	Cytogenetics User handbook		
Reference:	NC163F6	Version:	2
Active date:	January 2025	Pages:	Page 21 of 21
Owner	Lara Cresswell	Author	Lara Cresswell

Haemato-oncology FISH	New AML/ALL/CML & relapse samples	3 days	Where treatment stratification is required
	Non-acute requests	21 days	CLL/Myeloma
Molecular pathology PCR		14 days	JAK2 V617F
Solid cancer NGS testing		14 days	Lung cancer Colorectal cancer Melanoma

- Please note that QF-PCR testing undertaken at CUH for FASP referrals has a turnaround time of 3 calendar days from receipt in the CUH laboratory

The laboratory has specific criteria for its urgent requests.

- Newborn babies under 1 month old
- Diagnostic testing on proband and or parental samples where the mother is pregnant
- New acute leukaemia or CML cases and where relapse is suspected

We will endeavour to meet appointment dates; please record this information on the referral form. If a result is required urgently and is not one of the above categories please record this on the referral form, including a statement of why this is urgent, or contact the laboratory.